Amedisys (AMED)
(Delayed Data from NSDQ)
$90.40 USD
-0.38 (-0.42%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $90.43 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Amedisys (AMED) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$100.88 | $101.00 | $100.00 | 11.13% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Amedisys comes to $100.88. The forecasts range from a low of $100.00 to a high of $101.00. The average price target represents an increase of 11.13% from the last closing price of $90.78.
Analyst Price Targets (8 )
Broker Rating
Amedisys currently has an average brokerage recommendation (ABR) of 2.55 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 2.58 a month ago based on 12 recommendations.
Of the 11 recommendations deriving the current ABR, two are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 18.18% and 9.09% of all recommendations. A month ago, Strong Buy made up 16.67%, while Buy represented 8.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 8 | 8 | 9 | 9 | 9 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 1 | 1 |
ABR | 2.55 | 2.55 | 2.58 | 2.77 | 2.77 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/26/2024 | Raymond James | John W Ransom | Hold | Hold |
2/16/2024 | Stephens | Scott Fidel | Hold | Hold |
2/1/2024 | The Benchmark Company | William Sutherland | Hold | Hold |
12/1/2023 | SVB Securities | Whit Mayo | Hold | Hold |
11/21/2023 | Cantor Fitzgerald & Co | Sarah James | Strong Buy | Hold |
10/25/2023 | William Blair | Matt Larew | Strong Buy | Strong Buy |
10/11/2023 | Truist Securities | David S Macdonald | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.55 |
ABR (Last week) | 2.55 |
# of Recs in ABR | 11 |
Average Target Price | $100.88 |
LT Growth Rate | 4.70% |
Industry | Medical - Outpatient and Home Healthcare |
Industry Rank by ABR | 88 of 252 |
Current Quarter EPS Est: | 1.01 |